PD-1 inhibits T cells, and drugs targeting PD-1 and PD-L1 have shown promising efficacy in the treatment of a number of highly immunogenic tumors (non-Hodgkin’s lymphoma, non-small cell lung cancer, and melanoma) [20, 21]. Here, CD274 is linked to non-small cell lung carcinoma.